MedPath

The Possible Influence of Different Follow-up Modalities on Overall Survival in Ovarian Cancer

Terminated
Conditions
Patient Reported Outcome Measures
Ovarian Neoplasms
Registration Number
NCT05352217
Lead Sponsor
Stiftung Swiss Tumor Institute
Brief Summary

The study is designed as an observational cohort study, aiming to evaluate, whether a structured recording of symptoms by a mobile app contributes insight in the follow-up modalities of ovarian cancer patients.

Detailed Description

The observational study will examine different follow-up modalities for ovarian cancer patients with the ultimate goal of improving follow-up strategies for an improved well-being and better clinical outcomes. The primary objective is to quantify the effects of conservative clinical diagnostics by collecting symptoms via ePRO in addition to intensive diagnostics (CA-125 testing, imaging diagnostics) during follow-up, on survival, time to clinical recurrence and well-being.

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
7
Inclusion Criteria
  • Women aged ≥ 18 years
  • Between diagnosis and the first follow-up visit after the end of their antineoplastic treatment (systemic therapy or surgical treatment) for ovarian cancer.
  • German, English, French, or Italian speaking
  • Personal smartphone (iOS or Android system); one of the latest three main versions
Exclusion Criteria

• Patients whose compliance must be questioned, e.g. due to a psychiatric disorder, private life situation or insufficient knowledge on smartphone use and do not have a suitable caregiver to assist them with symptom reporting.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Overall survival three years after end of therapy3 years

Overall survival three years after the end of primary therapy / start of follow-up

Secondary Outcome Measures
NameTimeMethod
Time to Recurrence3 years

Time to Recurrence

Total number of tumor relapses3 years

Total number of tumor relapses occurring in the follow-up period

Symptoms that led to further diagnostic measures and possibly the detection of tumor relapse3 years

Symptoms that led to further diagnostic measures (imaging diagnostics and CA-125 testing) and possibly the detection of tumor relapse

Number and type of unplanned hospitalizations and emergencies.3 years

Unplanned hospitalizations and emergencies are defined as additional consultations outside of planned therapy or control visits at the treatment center or with the investigator, as well as unplanned visits to other physicians (e.g., GP) or emergency services.

Amount and frequency of patient data entries3 years

Amount and frequency of patient data entries

Platinum-sensitivity and the patients' platinum free interval (PFI)3 years

Platinum-sensitivity and the patients' platinum free interval (PFI)

Well-being3 years

Well-being according to the ECOG Performance Status

GRADE ECOG PERFORMANCE STATUS 0 Fully active, able to carry on all pre-disease performance without restriction

1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work

2. Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours

3. Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours

4. Completely disabled; cannot carry on any selfcare; totally confined to bed or chair

5. Dead

Trial Locations

Locations (4)

Spital Limmattal Frauenklinik

🇨🇭

Schlieren, Zürich, Switzerland

Gynäkologische Onkologie Spital Zollikerberg

🇨🇭

Zollikerberg, Zürich, Switzerland

Interdisziplinäre Medizin Zürich (IMZ)

🇨🇭

Zürich, Switzerland

Praxis für Gynäkologie und Geburtshilfe

🇨🇭

Zürich, Switzerland

© Copyright 2025. All Rights Reserved by MedPath